Completado

Bupropion Stereoselective Pharmacokinetics and CYP2D6 Inhibition in Healthy Volunteers

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está evaluando

Bupropion

Medicamento
Quiénes están siendo reclutados

Enfermedad

+ Procesos Patológicos

+ Condiciones Patológicas, Signos y Síntomas

De 18 a 55 años
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Estudio de Ciencia Básica

Fase Temprana 1
Intervencional
Inicio del estudio: junio de 2018
Ver detalles del protocolo

Resumen

Patrocinador PrincipalIndiana University
Última actualización: 28 de enero de 2026
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 5 de junio de 2018

Fecha en la que se inscribió al primer participante.

This study focuses on understanding how the drug bupropion is processed in the body, specifically in healthy volunteers. Bupropion is a medication often used to help people quit smoking or manage depression. The study aims to thoroughly examine how bupropion and its byproducts behave in the body over time. Additionally, it seeks to determine how bupropion interacts with an enzyme called CYP2D6, which plays a crucial role in breaking down many medications. Participants in this study will have their blood tested to measure the levels of bupropion and its byproducts, as well as the activity of the CYP2D6 enzyme. The primary outcome of the study is to measure the exposure to bupropion and its metabolites, as well as the activity of CYP2D6, by looking at the area under the plasma concentration versus time curves. This will help researchers understand the onset, extent, and offset of CYP2D6 inhibition in relation to the pharmacokinetic profiles of bupropion and its metabolites.

Título OficialBupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers
Patrocinador PrincipalIndiana University
Última actualización: 28 de enero de 2026
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño

Se reclutarán 28 pacientes

Número total de participantes que el ensayo clínico espera reclutar.

Estudio de Ciencia Básica

Los estudios de ciencia básica ayudan a los investigadores a comprender cómo funciona el cuerpo o cómo se desarrolla una enfermedad. No prueban tratamientos, pero sientan las bases para terapias futuras.



Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Cualquier sexo

Sexo biológico de los participantes elegibles para inscribirse.

De 18 a 55 años

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

EnfermedadProcesos PatológicosCondiciones Patológicas, Signos y Síntomas

Criterios

Inclusion Criteria: * Male and female (approximately 1:1) volunteers between the age of 18 and 55 years old and within 32% of your ideal body weight. * Judged healthy without any significant medical condition as determined by and decided from a pre-enrollment screening session that include medical history, laboratory tests such as blood and urine tests, and an electrical tracing of the heart beat (electrocardiogram, EKG). * Individuals who agree to refrain from taking any prescriptions medications, over-the-counter medications, and herbal, dietary, and alternative supplements that may interact with the metabolism of those study drugs at least 2 weeks prior to the start of the study and until study completion. * Nonsmoker or individuals willing to refrain from smoking or use of tobacco or marijuana for at least two weeks prior to and until the completion of the study (the entire study lasts for approximately 32 days). * Willing to commit the time requested for this study Exclusion Criteria: Subjects will be excluded from the study if they: * Are underweight (weigh less than 52 kg or 114 lb) or overweight \[body mass index (BMI) greater than 32\]. * Have laboratory results that do not fall in a healthy range (e.g., blood hemoglobin less than 12.0 mg/dl). * Have baseline EKG readings that are abnormal that could place the patient at the higher risk as decided by the study medical doctor (MD) * Have history of intolerance, allergic reactions (e.g. rash) or other forms of hypersensitivities to any of the study medications (dextromethorphan and bupropion). * Have current alcohol (more than 4 alcoholic drinks per day on a regular basis) or drug abuse. * Have history or current gastrointestinal (digestive) disorders such as persistent diarrhea or malabsorption that would interfere with the absorption of orally administered drugs * Have history or current seizures, hypertension and heart disease or any other cardiovascular disorders * Have history or current psychiatric (mental or brain) disorders (e.g., feeling sad or unhappy, loss of interest in normal activities, worried) such as depression, anxiety, or suicidality or suicide attempts. * Have significantly compromised liver and/or kidney functions. * Have participated in a research study involving intensive blood sampling or have donated blood within the past two months * Are unable or unwilling to stop taking other substances that may interfere with the metabolism of the study drugs (bupropion and dextromethorphan) two weeks prior to and during the entire study period, including prescription medications, over-the-counter medications, herbal or dietary supplements, and alternative medicines. * Are employees or students under supervision of any of the study investigators. * Cannot state a good understanding of this study including risks and requirements; are unable to follow the rules of this study. * Cannot commit the time requested for this study.

Plan de Estudio

Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.
Grupos de Tratamiento
Objetivos del Estudio

3 grupos de intervención están designados en este estudio

0% de probabilidad de ser asignado al grupo placebo

Grupos de Tratamiento

Grupo I

Experimental
CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug at baseline (control).

Grupo II

Experimental
CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug after 14 days pretreatment with bupropion (150 mg twice daily PO).

Grupo III

Experimental
The effect of a single dose of bupropion (150 mg PO) on CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug.

Objetivos del Estudio

Objetivos Primarios

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene una ubicación

Suspendido

Indiana Clinical Research Center (ICRC)

Indianapolis, United StatesAbrir Indiana Clinical Research Center (ICRC) en Google Maps
Completado1 Centros de Estudio